The Cancer and Blood Disorders program at Arkansas Children’s Hospital (ACH) has received internationally recognized accreditation by the Foundation for the Accreditation of Cellular Therapy (FACT), designating the program as offering the highest quality patient care.
By demonstrating compliance with the FACT’s international standards, Arkansas Children’s Hospital has earned three-year accreditation for pediatric autologous hematopoietic progenitor cellular therapy and peripheral blood cellular therapy product collection.
“Achieving FACT accreditation means Arkansas Children’s Hospital is providing the best care possible for children in Arkansas who are facing cancer and blood disorders,” said Rick Barr, MD, MBA, chief clinical officer of Arkansas Children’s. “These families face a long journey through cancer, and we are improving that experience by ensuring they can receive the highest quality care through accredited bone marrow transplants closer to home. We are grateful for the hard work of every member of our Cancer and Blood Disorders team to reach this vital accreditation.”
FACT is an internationally recognized accrediting body for hospitals and medical institutions offering stem cell transplant, and indicates Arkansas Children’s Hospital has met the most rigorous standards in every aspect of stem cell therapy. This covers the entire spectrum of stem cell therapy, from clinical care to donor management, cell collection, processing, storage, transportation, administration, and cell release.
Accreditation is attained through evaluation of submitted documentation and on-site inspection to determine if an organization is in compliance with current FACT standards and the United States Food and Drug Administration’s current rules for Good Tissue Practice. FACT Standards are defined by leading experts based on the latest knowledge of the field of cellular therapy.